Displaying 221–230 of 304 research results
Oct 11, 2016
Dr. Shinya Yamanka discussed his early clinical trial for iPSC-derived retinal pigment epithelial (RPE) cells for a 78-year-old woman with advanced wet age-related macular degeneration (AMD).
Oct 6, 2016
The complex and elusive nature of these conditions can also extend to the way they are passed down in families, making diagnosis and prognosis quite challenging.
Sep 6, 2016
The investigators found that in canines, the retinal degeneration is remarkably similar to that in humans with NPHP5 mutations.
Aug 18, 2016
RetroSense’s optogenetic therapy is designed to restore vision to people who are completely blind from retinal degenerative diseases such as retinitis pigmentosa by bestowing light sensitivity to retinal ganglion cells, which survive after photoreceptors, the cells that make vision possible, are lost.
Aug 2, 2016
Both approaches show strong, near-term potential for providing meaningful vision to people who are otherwise blind from retinal diseases such as retinitis pigmentosa and age-related macular degeneration (AMD).
Jul 21, 2016
The trial is one of the first-ever for a stem-cell-derived therapy for RP.
Jul 1, 2016
At VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
Jul 1, 2016
Dr. Weleber became the 10th recipient of the Foundation’s highest honor, named after FFB co-founder Lulie Gund, during the opening lunch of the VISIONS 2016 conference.
Jun 27, 2016
The story of Two Blind Brothers, a luxury clothing line that donates its proceeds to retinal research.
Jun 24, 2016
Subretinal injection is the most common form of delivery for gene therapies currently in clinical trials.